Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

This study found that in healthy adult women, a collagen and antioxidant-rich treatment significantly improved skin elasticity, hydration, texture, and reduced wrinkles and hair fall over 56 days compared to a placebo, indicating its efficacy and safety.

This study found that 2.2% minoxidil gel was more effective than placebo in treating alopecia areata and reported similar safety outcomes between the two groups.

This placebo-controlled study found that topical procyanidin B2 significantly increased total and anagen hair counts in men with androgenetic alopecia over 16 weeks compared to placebo, suggesting it as an effective and safe treatment option.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

This study found that both ciclosporin A and topical therapy were effective in reducing alopecia and scaling in dogs with idiopathic sebaceous adenitis, with evidence suggesting improved outcomes when both treatments are combined.

In this study, pioglitazone treatment in insulin-resistant PCOS patients decreased relative 5alpha-reductase activity without significantly affecting cortisol levels or urinary cortisol excretion.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This study evaluates finasteride's safety and efficacy for treating male chronic pelvic pain syndrome, but the abstract does not report any results.

PRP treatment increased hair density, especially in men and younger patients with AGA.

This study reported that canine recombinant IFNγ (KT‐100) significantly improved atopic dermatitis symptoms in dogs compared to placebo, and it appeared to be safe during the study period.

This study demonstrated that while the proposed placebo microneedle stamp design was partially successful in blinding participants with low skin sensitivity, further development of suitable placebo controls is needed.

This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.

This study found that 1mg/day oral finasteride significantly improved androgenetic alopecia in Chinese men, with a higher efficacy rate compared to placebo and minimal adverse effects.

In this placebo-controlled clinical study, a cream containing 4% capryloyl glycine and 1% glycine soy‐fermented extract effectively inhibited ODC1 activity and improved hypertrichosis in 91.7% of Caucasian female patients on the forearms, whereas no improvement was observed with the placebo.

This letter challenges an interpretation of results from a zinc lozenge trial that suggested patient perceptions of receiving treatment might indicate effective blinding, arguing this only holds for crossover studies.

This double-blind randomized placebo-controlled study found that a shampoo containing salicylic acid, panthenol, and niacinamide significantly increased hair count and improved hair loss symptoms in alopecia patients over 24 weeks, compared to a placebo, with no abnormal symptoms reported.

This study in Bangladesh reports that 81% of patients with refractory idiopathic hematospermia showed remission after three months of finasteride treatment, significantly higher than the 27% remission rate in the placebo group, with results sustained for some time after stopping the medication.

This commentary discusses challenges in maintaining proper blinding in placebo-controlled trials, illustrated by a study where zinc and placebo lozenges were nearly indistinguishable in taste by participants.

In this randomized controlled trial, researchers found that participants with androgenic alopecia taking an Annurca apple extract supplement showed significant increases in hair density and weight and reduced hair loss compared to a placebo, with good skin and gastrointestinal tolerability over 180 days.